Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19078920 | 1.00 | SSTR1 (0.34) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12416160 | 0.86 | — | — | |
| SCHEMBL19051013 | 0.86 | — | — | |
| SCHEMBL19760424 | 0.86 | — | — | |
| SCHEMBL19078924 | 0.86 | — | — | |
| SCHEMBL10366417 | 0.82 | FGF1 (0.31) | — | |
| SCHEMBL25594520 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL18294595 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL19051014 | 0.82 | FGF1 (0.33) | — | |
| SCHEMBL25594518 | 0.82 | FGF1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026360-A1 | OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION | HOFFMANN LA ROCHE (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230257748-A1 | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667660-B2 | Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-06-06 | — | — | US | disclosed |
| US-20230132093-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | CODIAK BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20180002701-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION | HOFFMANN-LA ROCHE INC. | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132093-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | NLRP3, MTREX, NOD1 | SSTR1 3967/4885SSTR2 4009/4885SSTR4 3924/4885 |
| US-11667660-B2 | Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides | RNGTT, CPSF6, NUDT1 | SSTR1 1405/4885SSTR2 2198/4885SSTR4 806/4885 |
| US-20230257748-A1 | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | BCDIN3D, SNRPF, U2AF2 | SSTR1 4350/4885SSTR2 4089/4885SSTR4 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.